These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 14703941)

  • 1. HIV, HAART, and hyperlipidemia: balancing the effects.
    Sherer R
    J Acquir Immune Defic Syndr; 2003 Oct; 34 Suppl 2():S123-9. PubMed ID: 14703941
    [No Abstract]   [Full Text] [Related]  

  • 2. Does antiretroviral-induced hyperlipidaemia constitute a cardiovascular risk?
    Gilleece Y; Nelson M
    J HIV Ther; 2001 May; 6(2):37-9. PubMed ID: 11501202
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cardiovascular risk factors associated with antiretroviral therapy].
    Pérez-Camacho I; Camacho A; Torre-Cisneros J; Rivero A
    Enferm Infecc Microbiol Clin; 2009 Sep; 27 Suppl 1():24-32. PubMed ID: 20172412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of treatment-induced lipid abnormalities and lipodystrophy.
    Smith D
    J HIV Ther; 2001 May; 6(2):25-7. PubMed ID: 11501199
    [No Abstract]   [Full Text] [Related]  

  • 5. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
    Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Introduction. Cardiovascular disease and HIV infection].
    Martínez E
    Enferm Infecc Microbiol Clin; 2009 Sep; 27 Suppl 1():1-2. PubMed ID: 20213896
    [No Abstract]   [Full Text] [Related]  

  • 7. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pravastatin in hyperlipidemia secondary to HIV protease inhibitors without response to fenofibrate: a brief preliminary report.
    de Luis DA; Bachiller P; Aller R; Eiros Bouza J; Izaola O
    Nutrition; 2003 Oct; 19(10):903-4. PubMed ID: 14559329
    [No Abstract]   [Full Text] [Related]  

  • 9. HIV-HCV Co-infection therapeutic outcomes have not improved over time.
    Cooper C; Costiniuk C; Giguère P
    HIV Clin Trials; 2009; 10(3):203-6. PubMed ID: 19632960
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study.
    Baldini F; Di Giambenedetto S; Cingolani A; Murri R; Ammassari A; De Luca A
    AIDS; 2000 Jul; 14(11):1660-2. PubMed ID: 10983656
    [No Abstract]   [Full Text] [Related]  

  • 11. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
    Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
    J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent developments in HIV research.
    Boyle BA
    AIDS Read; 2002 Sep; 12(9):390-4, 407. PubMed ID: 12402802
    [No Abstract]   [Full Text] [Related]  

  • 13. [Metabolic disturbances associated with HAART].
    Olczak A
    Przegl Epidemiol; 2007; 61(4):639-46. PubMed ID: 18572495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic complications of HIV and AIDs.
    Briggs JM; Drabek CA
    Orthop Nurs; 2001; 20(4):41-50. PubMed ID: 12025672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alopecia universalis and Graves' disease in the setting of immune restoration after highly active antiretroviral therapy.
    Sereti I; Sarlis NJ; Arioglu E; Turner ML; Mican JM
    AIDS; 2001 Jan; 15(1):138-40. PubMed ID: 11192862
    [No Abstract]   [Full Text] [Related]  

  • 16. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy.
    Hatano H; Miller KD; Yoder CP; Yanovski JA; Sebring NG; Jones EC; Davey RT
    AIDS; 2000 Sep; 14(13):1935-42. PubMed ID: 10997397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin for protease inhibitor-related hyperlipidaemia.
    Murillas J; Martín T; Ramos A; Portero JL
    AIDS; 1999 Jul; 13(11):1424-5. PubMed ID: 10449305
    [No Abstract]   [Full Text] [Related]  

  • 18. Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient.
    Deeks SG; Martin JN
    AIDS; 2001 Jan; 15(1):117-9. PubMed ID: 11192853
    [No Abstract]   [Full Text] [Related]  

  • 19. Simplifying suppression: switching therapies to improve HIV disease management.
    Moyle GJ
    AIDS Read; 2004 Jul; 14(7):380-4. PubMed ID: 15282867
    [No Abstract]   [Full Text] [Related]  

  • 20. Adherence and potency with antiretroviral therapy: a combination for success.
    Gathe J
    J Acquir Immune Defic Syndr; 2003 Oct; 34 Suppl 2():S118-22. PubMed ID: 14703940
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.